Reply

Introduction It is common practice to put patients with chronic kidney disease (CKD) on an activated form of vitamin D such as alphacalcidol without measuring or correcting the vitamin D3 level. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the management...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of Saudi medicine Vol. 33; no. 2; p. 201
Main Author:	Kari, Jameela Abdulaziz
Format:	Journal Article
Language:	English
Published:	Riyadh KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE 01-03-2013
Subjects:	Bone diseases Clinical medicine Kidney diseases Vitamin D Vitamin deficiency New Zealand Australia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction It is common practice to put patients with chronic kidney disease (CKD) on an activated form of vitamin D such as alphacalcidol without measuring or correcting the vitamin D3 level. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the management of CKD-MBD recommended that 25 (OH) D3 levels should be monitored and if low, ergo- or cholecalciferol supplements should be prescribed. 3 We have conducted a study investigating the effect of daily oral vitamin D3 on the levels of 25(OH) D3 and iPTH in vitamin D insufficient/ deficient children with CKD.4 Maintenance therapy with oral vitamin D3 (2000 IU/day for 6 months) did not result in improved iPTH levels, and only 11% of the children achieved normal 25 (OH) D3 levels (≥30 ng/mL). "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)" .
ISSN:	0256-4947 0975-4466